Skip to content
DataLookout
Menu

COATLNCT07075146

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 5, 2026 to Dec 5, 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 19 words
    • Primary endpoints: details revised at 2 of 2 entries
    • Interventions: BIC/FTC/TAF (Drug), DOR/3TC/TDF (Drug) to BIC/FTC/TAF (Drug), DOR/3TC/TDF (Drug)
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 17 words
    • Publications: details revised at 1 of 2 entries
  2. Notable Lead sponsor: Instituto Mexicano del Seguro Social to José Antonio Mata Marín
    • Primary endpoints revised (2)
    • Collaborators expanded, about 5 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

To determine the safety and tolerability of Doravirine/Lamivudine/Tenofovir compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine in ART-naive people living with HIV at 144 weeks of treatment.
Timeframe: 144 weeks
Evaluate the effectiveness and safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Timeframe: 144 weeks of follow-up with interim analysis at 48 and 96 weeks

Secondary (4)

To compare changes in lipid profile in people living with HIV (PLWH) treated with Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate versus Bictegravir/Emtricitabine/Tenofovir Alafenamide after initiating ART
To compare changes in body composition in PLWH treated with Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate versus Bictegravir/Emtricitabine/Tenofovir Alafenamide before initiating ART
To compare changes in estimated glomerular filtration rate (eGFR) in PLWH treated with Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate versus Bictegravir/Emtricitabine/Tenofovir Alafenamide after initiating TAR
To compare changes in cardiovascular risk using the Framingham Risk Score and the Pooled Cohort Equations (ASCVD AHA/ACC) in PLWH treated with Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate versus Bictegravir/Emtricitabine/Tenofovir Alafenamide

Arms and interventions

BIC/TAF/FTCActive comparator

Bictegravir/ tenofovir alafenamide/ emtricitabine 50/ 25/ 200 mg. It is the usual therapy, consisting of 3 drugs in a single tablet, based on an integrase inhibitor, and 2 nucleoside analogues, it is the experimental group

DOR/3TC/TDFExperimental

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100/300/300 mg Non-nucleoside reverse transcriptase inhibitor (doravirine) Nucleoside reverse transcriptase inhibitors (lamivudine, tenofovir disoproxil fumarate)

Drugs: DOR/3TC/TDF, BIC/FTC/TAF

Sites

1 site in 1 country

  • Hospital de infectología, Centro Médico Nacional La RazaMexico City, Mexico